CareDx sells Lab Products to Eurobio for $170M; Q1 rev up 39% to $118M

CareDx, Inc.

Divests Lab Products (IVD kits) to Eurobio Scientific for $170M cash; expected close by end of Q3 2026.
Preliminary Q1 2026 revenue ~$118M (+39% YoY); Testing Services revenue ~$91M (+48% YoY) on volume of ~54,900 (+17%).
Patient & Digital Solutions revenue ~$16M (+33% YoY); Lab Products revenue ~$10M (-4% YoY).
Cash, equivalents, and marketable securities ~$198M as of Mar 31, 2026.
Retains exclusive North American distribution rights for certain Eurobio post-transplant monitoring IVD tests.

item 1.01 item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CareDx, Inc. reported first quarter of 2026 results: revenue approximately $118 million.

Period: first quarter of 2026
Revenue: approximately $118 million
Result: preliminary results

Exact text from the filing

Revenue of approximately $118 million, growth of 39% year-over-year

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CareDx, Inc. entered into Purchase Agreement with Eurobio Scientific S.A. valued at $170 million in cash (effective 2026-04-15).

Action: entry
Agreement: asset purchase
Counterparty: Eurobio Scientific S.A.
Value: $170 million in cash
Effective: 2026-04-15

Exact text from the filing

On April 15, 2026, CareDx, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Eurobio Scientific S.A. (“Eurobio”), pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell to Eurobio the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company’s kitted laboratory products business and related software (the “Business”) for $170 million in cash

View on SEC.gov

Browse all earnings releases →

CareDx, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-043970

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.